Strongbridge Biopharma plc to Report Second Quarter 2021 Financial Results on August 5, 2021
DUBLIN, Ireland and TREVOSE, Pa. – Strongbridge Biopharma (Nasdaq: SBBP) will report its Q2 2021 financial results and corporate updates on August 5, 2021, at 7:30 a.m. ET. Strongbridge is focused on developing therapies for rare diseases. Key products include RECORLEV, an adrenal steroidogenesis inhibitor under FDA review for Cushing’s syndrome, and KEVEYIS, the only FDA-approved treatment for specific types of periodic paralysis. Both RECORLEV and veldoreotide have received orphan drug designations.
- Strongbridge's RECORLEV is under FDA review, potentially expanding its treatment portfolio.
- The company has an established rare endocrine franchise with significant market potential.
- Both RECORLEV and veldoreotide received orphan drug designation, enhancing exclusivity.
- None.
DUBLIN, Ireland and TREVOSE, Pa., July 29, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that it will report the Company’s second quarter 2021 financial results and corporate highlights on August 5, 2021 at 7:30 a.m. ET.
About Strongbridge Biopharma
Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Strongbridge’s rare endocrine franchise includes RECORLEV® (levoketoconazole), an adrenal steroidogenesis inhibitor with a New Drug Application that is currently under review by the FDA for the treatment of endogenous Cushing’s syndrome, and veldoreotide extended release, a pre-clinical next-generation somatostatin analog being investigated for the treatment of acromegaly and potential additional applications in other conditions amenable to somatostatin receptor activation. Both RECORLEV and veldoreotide have received orphan drug designation from the FDA and the European Medicines Agency. The company’s rare neuromuscular franchise includes KEVEYIS® (dichlorphenamide), the first and only FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. KEVEYIS has orphan drug exclusivity in the United States.
Contacts:
Corporate and Media Relations
Elixir Health Public Relations
Lindsay Rocco
+1 862-596-1304
lrocco@elixirhealthpr.com
Investor Relations
Solebury Trout
Mike Biega
+1 617-221-9660
mbiega@soleburytrout.com
FAQ
When will Strongbridge Biopharma report its Q2 2021 financial results?
What is RECORLEV and what condition is it being reviewed for?
What is KEVEYIS and what is its significance?
